Optimizing Outcomes in HR+/HER2-Metastatic Breast Cancer: Molecular Testing and Targeted Strategies - Episode 3
Selecting the Optimal CDK4/6 Regimen for First-Line Therapy
Video content above is prompted by the following:
- Dr. O’Shaughnessy to Dr. Conlin: What is your preferred CDK4/6 regimen in the first-line metastatic setting?
- How do patient factors like visceral crisis, bone-only disease, or comorbidities influence your decision?
- What toxicity concerns inform your choice of CDK4/6 inhibitor?